Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Dapagliflozin reduces IL-1B but does not improve cardiac fibrosis in T2D patients.
Última actualización 6 de julio de 2026
Key finding
Plasma IL-1B was reduced (−1.8 pg/mL, P = 0.003)
This study investigated the effects of dapagliflozin on cardiovascular outcomes in diabetic patients, revealing significant changes in plasma IL-1B and ketones.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of dapagliflozin on cardiovascular outcomes in diabetic patients, revealing significant changes in plasma IL-1B and ketones.
Clinical relevance
These findings suggest that dapagliflozin may provide cardiovascular benefits for diabetic patients by reducing inflammation and altering metabolic markers. Understanding these mechanisms could lead to better management strategies for diabetes-related cardiovascular risks.
Keep in mind
Limited to a specific population of diabetic patients. Short follow-up period of 12 months may not capture long-term effects. No significant changes in several cardiovascular metrics.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Dennis DW, Anna VN, Daniel I, et al. Sodium glucose cotransporter 2 inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. Cardiovascular Diabetology. 2024;23:197. doi:10.1186/s12933-024-02294-z
Efectos Principales
Plasma IL-1B was reduced by −1.8 pg/mL (P = 0.003).
Plasma ketones increased by 0.26 mM (P = 0.0001).
PBMC maximal oxygen consumption rate did not change in the dapagliflozin group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dapagliflozin and Extracellular volume, Global myocardial strain, Plasma IL-1B, and 2 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
- Extracellular volume
- Global myocardial strain
- Plasma IL-1B
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
5
Evidence pairs
19
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
SGLT2 Inhibitors
matched_intervention
Core evidence
Study findings
The primary outcomes reported in this study.
Global myocardial strain
Dapagliflozin → Global myocardial strain
Dapagliflozin → Global myocardial strain
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerT2 relaxation time change
Dapagliflozin → T2 relaxation time change
Dapagliflozin → T2 relaxation time change
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- Dapagliflozin significantly reduced plasma IL-1B levels.
- Plasma ketones increased significantly with dapagliflozin treatment.
- PBMC maximal oxygen consumption rate decreased in the placebo group.
A quién se aplica
- Adults with type 2 diabetes.
- Patients at risk for cardiovascular disease.
Tener en Cuenta
- Results may not be generalizable to non-diabetic populations.
- Further studies are needed to explore long-term effects.
- The study did not measure all potential cardiovascular outcomes.
Entre Líneas
- Limited to a specific population of diabetic patients.
- Short follow-up period of 12 months may not capture long-term effects.
- No significant changes in several cardiovascular metrics.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Extracellular volume, SGLT2 Inhibitors and Global myocardial strain.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceSGLT2 Inhibitors → Extracellular volume
Medications
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceSGLT2 Inhibitors → Global myocardial strain
Medications
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Extracellular volume Evidence Hub
All studies measuring Extracellular volume
1 studies
outcome_hubMeasures Extracellular volume as a key outcome.
Global myocardial strain Evidence Hub
All studies measuring Global myocardial strain
1 studies
outcome_hubMeasures Global myocardial strain as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
1 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Dapagliflozin and Extracellular volume
Intervention: DapagliflozinOutcome: Extracellular volume
1 results
All studies on Dapagliflozin and Global myocardial strain
Intervention: DapagliflozinOutcome: Global myocardial strain
1 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
1 results
All studies measuring Extracellular volume
Outcome: Extracellular volume
1 results
All studies measuring Global myocardial strain
Outcome: Global myocardial strain
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Dapagliflozin improve plasma il-1b?
Emerging Evidence
Dapagliflozin appears to improve Plasma IL-1B.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Plasma IL-1B
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Dapagliflozin improve plasma ketones?
Emerging Evidence
Dapagliflozin appears to improve Plasma ketones.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Plasma ketones
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Dapagliflozin improve extracellular volume?
Emerging Evidence
Current evidence does not show a clear benefit of Dapagliflozin for Extracellular volume.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Extracellular volume
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Dapagliflozin improve global myocardial strain?
Emerging Evidence
Current evidence does not show a clear benefit of Dapagliflozin for Global myocardial strain.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Global myocardial strain
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Dapagliflozin improves metabolic outcomes in type 2 diabetes patientsDapagliflozin may improve RAAS markers in diabetes patientsDapagliflozin shows no long-term harm to bone health in women with diabetesDapagliflozin-linagliptin combo improves glycemic control and organ protectionDapagliflozin improves brain function in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.